A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease
Latest Information Update: 11 Apr 2024
At a glance
- Drugs CB-AC 02 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors CHA Bio & Diostech
- 06 Feb 2024 Planned End Date changed from 1 Dec 2021 to 1 Dec 2024.
- 06 Feb 2024 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2024.
- 06 Feb 2024 Status changed from recruiting to active, no longer recruiting.